The F.D.A. has allowed 23andMe to market genetic tests for mutations directly to the public. The agency said that, for the most part, so-called carrier tests would no longer need advance approval before being marketed this way. But 23andMe is also offering access to its data for research, opening up questions about privacy and anonymity.
Should commercial companies share genetic information for research purposes? Is it an invasion of privacy or is the potential for scientific breakthrough more important?
Responses:
There's No Guarantee
Ifeoma Ajunwa, law professor
A Path to Better Health Care Research
Somalee Datta, director, Bioinformatics at Stanford
A Dangerous Business Model
Marcy Darnovsky, Center for Genetics and Society
Insure People Against Genetic Data Breaches
Frank Pasquale, author, "The Black Box Society"
